Australian (ASX) Stock Market Forum

RNV - ReNerve Limited

Joined
27 June 2010
Posts
4,147
Reactions
309
ReNerve Limited is a medical device company developing tissue-based products for peripheral nerve repair and replacement and, other related soft tissue surgical procedures. The company is focused on improving outcomes for patients by creating the ideal healing environment for soft tissue repairs and the related regeneration.

ReNerve has established laboratories in Melbourne, Australia and also works closely with researchers in one of Australia’s premier biomaterials precincts at the CSIRO/Monash University.

The company is focused on developing products that accelerate tissue regeneration while preventing scarring and negative inflammatory responses. The company's lead programs are focused on peripheral nerve repair; however, have the potential for application beyond peripheral nerve repair.

It is anticipated that RNV will list list on the ASX during November 2024.

 
Listing date
22 November 2024 : 12:00 PM AEST
Contact details
https://renerve.com.au/
Ph: +61 03 9482 3940

Principal Activities
ReNerve specialises in developing a range of 'ready to use' products that are cleaner, safer and better for the repair or replacement of damaged peripheral nerves resulting in better patient outcomes.

Issue Price
AUD 0.20
Issue Type
Ordinary Fully Paid Shares
Security code
RNV
Capital to be Raised
$7,000,000
Expected offer close date
15 November 2024
Underwriter
Not underwritten. Alpine Capital Pty Ltd (Lead Manager)
 
Top